Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial

View ORCID ProfileTimothy SC Hinks, Lucy Cureton, Ruth Knight, Ariel Wang, Jennifer L Cane, Vicki S Barber, Joanna Black, Susan J Dutton, James Melhorn, Maisha Jabeen, Phil Moss, Rajendar Garlapati, Tanya Baron, Graham Johnson, Fleur Cantle, David Clarke, Samer Elkhodair, Jonathan Underwood, Daniel Lasserson, Ian D Pavord, Sophie Morgan, Duncan Richards
doi: https://doi.org/10.1101/2021.04.21.21255807
Timothy SC Hinks
1Respiratory Medicine Unit and National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), Nuffield Department of Medicine Experimental Medicine, University of Oxford, OX3 9DU, Oxfordshire, UK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Timothy SC Hinks
  • For correspondence: timothy.hinks@ndm.ox.ac.uk
Lucy Cureton
2Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK
BSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth Knight
2Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ariel Wang
2Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer L Cane
1Respiratory Medicine Unit and National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), Nuffield Department of Medicine Experimental Medicine, University of Oxford, OX3 9DU, Oxfordshire, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vicki S Barber
2Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joanna Black
2Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan J Dutton
2Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Melhorn
3University Hospital Llandough, Cardiff, CF64 2XX, UK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maisha Jabeen
1Respiratory Medicine Unit and National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), Nuffield Department of Medicine Experimental Medicine, University of Oxford, OX3 9DU, Oxfordshire, UK
MBChB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Phil Moss
4Emergency Department Clinical Research Unit, St George’s Hospital, Tooting, London, SW17 0QT, UK
MB BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rajendar Garlapati
5Accident and Emergency, East Lancashire NHS Hospitals, Blackburn, UK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tanya Baron
6Emergency Department, Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, UK
MBChB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graham Johnson
MBChB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fleur Cantle
8Department of Emergency Medicine, King’s College Hospital, London, UK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Clarke
9Royal Berkshire Hospital, London Rd, Reading RG1 5AN
MBChB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samer Elkhodair
10Emergency Department, University College London Hospital, 250 Euston Road, 4th Floor East, London NW1 2PG
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Underwood
11Department of Infectious Diseases, Cardiff and Vale University Health Board, Cardiff, UK
12Division of Infection and Immunity, Cardiff University, Cardiff, UK
MBBS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Lasserson
13Dept of Geratology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, OX3 9DU, UK
14Dept of Acute Medicine, Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Birmingham B18 7QH, UK
15Warwick Medical School, University of Warwick, Coventry, CV4 7AL
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian D Pavord
1Respiratory Medicine Unit and National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), Nuffield Department of Medicine Experimental Medicine, University of Oxford, OX3 9DU, Oxfordshire, UK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophie Morgan
1Respiratory Medicine Unit and National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), Nuffield Department of Medicine Experimental Medicine, University of Oxford, OX3 9DU, Oxfordshire, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Duncan Richards
2Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK
DM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The antibacterial, anti-inflammatory and antiviral properties of azithromycin suggest therapeutic potential against COVID-19. Randomised data in mild-moderate disease are lacking. We assessed whether azithromycin is effective in reducing hospitalisation in patients with mild-moderate COVID-19.

Methods This open-label, randomised superiority clinical trial at 19 centres in the United Kingdom enrolled adults, ≥18 years, presenting to hospitals with clinically-diagnosed highly-probable or confirmed COVID-19 infection, with <14 days symptoms, considered suitable for initial ambulatory management. Patients were randomised (1:1) to azithromycin (500 mg daily orally for 14 days) or to standard care without macrolides. The primary outcome was the difference in proportion of participants with death or hospital admission from any cause over the 28 days from randomisation, assessed according to intention-to-treat (ITT). Trial registration: ClinicalTrials.gov, NCT04381962, Study closed.

Findings 298 participants were enrolled from 3rd June 2020 to 29th January 2021. The primary outcome was assessed in 292 participants. The primary endpoint was not significantly different between the azithromycin and control groups (Adjusted OR 0·91 [95% CI 0·43-1·92], p=0·80). Rates of respiratory failure, progression to pneumonia, all-cause mortality, and adverse events, including serious cardiovascular events, were not significantly different between groups.

Interpretation In patients with mild-moderate COVID-19 managed without hospital admission, adding azithromycin to standard care treatment did not reduce the risk of subsequent hospitalisation or death. Our findings do not support the use of azithromycin in patients with mild-moderate COVID-19.

Funding NIHR Oxford BRC, University of Oxford and Pfizer Inc.

Evidence before this study We searched MEDLINE and the Cochrane Central register of Controlled Trials (CENTRAL) with the terms (“azithromycin”) AND (“COVID” OR “COVID-19”) AND (“clinical trials”), until March 25, 2021, with no language restrictions. We identified 42 studies, among which there were four completed randomised trials of azithromycin (with or without hydroxychloroquine) in hospitalised patients with severe disease, and three completed randomised trials of azithromycin in mild COVID-19 in primary care. The four trials in hospitalised patients randomised 8,988 participants to azithromycin or standard care or hydroxychloroquine and found no evidence of a difference in mortality, duration of hospital stay or peak disease severity. Of the three trials in primary care, these randomised participants with early disease to 3 or 5 days of therapy, of which only one assessed azithromycin as standalone therapy. This large, adaptive platform trial in the UK randomised 540 participants in primary care to 3 days treatment with azithromycin versus 875 to standard care alone and found no meaningful difference in time to first reported recovery, or of rates of hospitalisation (3% versus 3%) and there were no deaths. We did not identify any randomised trials in patients with COVID-19 managed in ambulatory care.

Added value of this study The ATOMIC2 trial was uniquely-designed to assess azithromycin as a standalone therapy in those with mild-moderately COVID-19 presenting to emergency care, but assessed as appropriate for initial ambulatory management without hospital admission. ATOMIC2 also uniquely assessed high-dose, long-duration treatment to investigate the efficacy of putative anti-inflammatory effects. We found that azithromycin 500 mg daily for 14 days did not reduce the proportion of participants who died or required hospital admission from any cause over the 28 days from randomisation.

Implications of all the available evidence Our findings, taken together with existing data, suggest there is no evidence that azithromycin reduces hospitalisation, respiratory failure or death compared with standard care, either in early disease in the community, or those hospitalised with severe disease, or in those with moderate disease managed on an ambulatory pathway.

Competing Interest Statement

TSCH has received grants from Pfizer Inc., grants from University of Oxford, grants from the Wellcome Trust, grants from The Guardians of the Beit Fellowship, and grants from the NIHR Oxford Biomedical Research Centre during the conduct of the study; and personal fees from Astra Zeneca, personal fees from TEVA, personal fees from Peer Voice outside the submitted work. MJ has received grants from the University of Oxford and NIHR Oxford Biomedical Research Centre. DR has undertaken paid consultancy for GSK outside the submitted work. IDP reports personal fees from AstraZeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis, GlaxoSmithKline, Genentech, Regeneron, Teva, Chiesi, Sanofi, Circassia, Knopp, and grants from NIHR outside the submitted work. JU has received honoraria for preparation of educational materials and has served on an advisory board for Gilead Sciences and ViiV Healthcare outside of the submitted work. LC, RK, AW, JLC, VSB, JB, SJD, JM, PM, RG, TB, GJ, FC, DC, SE, DL and SM declare they have no competing interests.

Clinical Trial

NCT04381962

Clinical Protocols

https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04593-8

Funding Statement

This research is funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), by the University of Oxford and by an independent research grant from Pfizer Inc. TSCH is supported by a fellowship from the Wellcome Trust (211050/Z/18/z). This research is supported by the NIHR Applied Research Collaboration (ARC) West Midlands through funding to DSL. The funders played no role in the study design.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial protocol was reviewed and approved by the UK Medicines and Healthcare products Regulatory Agency and an independent ethical committee (London - Brent Research Ethics Committee, Research Ethics Committee reference number 20/HRA/2105).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data analysed and presented in this study are available from the corresponding author on reasonable request, providing the request meets local ethical and research governance criteria after publication. Patient-level data will be anonymised and study documents will be redacted to protect the privacy of trial participants. The study protocol is provided in the appendix.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted April 27, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial
Timothy SC Hinks, Lucy Cureton, Ruth Knight, Ariel Wang, Jennifer L Cane, Vicki S Barber, Joanna Black, Susan J Dutton, James Melhorn, Maisha Jabeen, Phil Moss, Rajendar Garlapati, Tanya Baron, Graham Johnson, Fleur Cantle, David Clarke, Samer Elkhodair, Jonathan Underwood, Daniel Lasserson, Ian D Pavord, Sophie Morgan, Duncan Richards
medRxiv 2021.04.21.21255807; doi: https://doi.org/10.1101/2021.04.21.21255807
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial
Timothy SC Hinks, Lucy Cureton, Ruth Knight, Ariel Wang, Jennifer L Cane, Vicki S Barber, Joanna Black, Susan J Dutton, James Melhorn, Maisha Jabeen, Phil Moss, Rajendar Garlapati, Tanya Baron, Graham Johnson, Fleur Cantle, David Clarke, Samer Elkhodair, Jonathan Underwood, Daniel Lasserson, Ian D Pavord, Sophie Morgan, Duncan Richards
medRxiv 2021.04.21.21255807; doi: https://doi.org/10.1101/2021.04.21.21255807

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (579)
  • Anesthesia (139)
  • Cardiovascular Medicine (1947)
  • Dentistry and Oral Medicine (252)
  • Dermatology (184)
  • Emergency Medicine (333)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (699)
  • Epidemiology (11102)
  • Forensic Medicine (8)
  • Gastroenterology (624)
  • Genetic and Genomic Medicine (3168)
  • Geriatric Medicine (308)
  • Health Economics (561)
  • Health Informatics (2042)
  • Health Policy (863)
  • Health Systems and Quality Improvement (782)
  • Hematology (310)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12720)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2986)
  • Nursing (164)
  • Nutrition (463)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1552)
  • Ophthalmology (477)
  • Orthopedics (185)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (403)
  • Pediatrics (912)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2785)
  • Public and Global Health (5591)
  • Radiology and Imaging (1094)
  • Rehabilitation Medicine and Physical Therapy (635)
  • Respiratory Medicine (760)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (289)
  • Surgery (343)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (132)